Placental growth factor as an indicator of fetal growth restriction in late-onset small-for-gestational age pregnancies by Anderson, Ngaire et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1111/ajo.12831
Document Version
Peer reviewed version
Link to publication record in King's Research Portal
Citation for published version (APA):
Anderson, N., De Laat, M., Benton, S., Von Dadelszen, P., & Mccowan, L. (2018). Placental growth factor as an
indicator of fetal growth restriction in late-onset small-for-gestational age pregnancies. Australian and New
Zealand Journal of Obstetrics and Gynaecology. https://doi.org/10.1111/ajo.12831
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 10. Jul. 2020
TITLE PAGE 
Placental growth factor (PlGF) as an indicator of fetal growth restriction in late-onset 
small for gestational age pregnancies. 
 
Dr Ngaire ANDERSON 
Senior Lecturer  
Department of Obstetrics and Gynaecology 
The University of Auckland 
Private Bag 92019 
Auckland 1142 
New Zealand 
Email ngaire.anderson@auckland.ac.nz 
Telephone 64 9 373 7599  ext. 87277 
Mobile 64 21 813 329 
Facsimile 64 9 303 5969 
 
Dr Monique DE LAAT 
Maternal Fetal Medicine Specialist 
National Women’s Hospital 
Auckland District Health Board 
Auckland 
New Zealand 
Email: MSteindeL@adhb.govt.nz 
 
Dr Samantha BENTON 
Postdoctoral Fellow 
Department of Cellular and Molecular Medicine 
University of Ottawa 
Ottawa 
Ontario 
Canada 
Email: sbenton@uottawa.ca 
 
Professor Peter VON DADELSZEN 
Department of Women’s Health 
Kings College London 
London 
United Kingdom 
Email: PVD@kcl.ac.uk 
 
Professor Lesley MCCOWAN 
Department of Obstetrics and Gynaecology 
The University of Auckland 
Auckland  
New Zealand 
Email: l.mccowan@auckland.ac.nz 
1 
 
 
 
Title: 1 
Placental growth factor (PlGF) as an indicator of fetal growth restriction in late-onset 2 
small for gestational age pregnancies. 3 
Short Title:  4 
PlGF and late onset fetal growth restriction 5 
Word Count: 6 
Abstract: 250 7 
Main Text:  2586 8 
Key Words: 9 
Fetal growth restriction, placental growth factor, perinatal outcome, small for 10 
gestational age 11 
  12 
2 
 
 
 
Abstract 13 
Background: At-risk small-for-gestational age (SGA) pregnancies in New Zealand 14 
are identified using Doppler ultrasound; fetuses with Doppler abnormalities are 15 
considered growth restricted (FGR). Low maternal PlGF has also been associated 16 
with late-onset FGR. 17 
Aims: Investigate whether low PlGF at diagnosis of late-onset SGA identifies the 18 
same fetuses classified FGR by detailed Doppler studies, and the association 19 
between low PlGF and adverse pregnancy outcomes. 20 
Methods: Among an historical database of normotensive suspected SGA 21 
pregnancies (fetal abdominal circumference <10th%ile) ≥32 weeks’ gestation, the 22 
ability of low PlGF (<5th%ile) to identify FGR infants was investigated. ‘Initial FGR’ 23 
was an abnormal umbilical artery resistance index (RI) or estimated fetal weight <3rd 24 
customised centile. ‘Secondary FGR’ was abnormal internal carotid RI, cerebro-25 
placental ratio and/or mean uterine artery RI. Development of hypertensive disease 26 
and adverse perinatal outcomes were compared by PlGF status. 27 
Results: Of 136 SGA pregnancies, 56 (41.1%) had initial FGR. Of the remaining, 20 28 
(25.0%) had secondary FGR, 17 (21.3%) low PlGF. The sensitivity of low PlGF 29 
identifying secondary FGR was 0.30 (95% CI 0.14-0.50), specificity 0.83 (0.70-0.92), 30 
positive predictive value 0.47 (0.23-0.72), negative predictive value 0.70 (0.57-0.81). 31 
Overall, low PlGF occurred in 44/136 (32.4%) pregnancies and was associated with 32 
gestational hypertensive disease (63.6% cf 15.2%, p<0.01), adverse perinatal 33 
outcome (34.1% cf 15.2%, p=0.01) and very low birthweight (customised centile 2.2 34 
cf 6.8, p<0.01). 35 
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Conclusions: At diagnosis of late-onset SGA, low PlGF was poor at identifying 36 
Doppler-defined FGR. Low PlGF identified pregnancies at risk of hypertensive 37 
disease, adverse perinatal outcome and very low birthweight. 38 
 39 
Introduction 40 
Fetuses with suboptimal growth due to utero-placental insufficiency are at increased 41 
risk of adverse consequences ranging from poor perinatal outcomes to abnormal 42 
neurodevelopment and long term cardiovascular risk.1,2 One of the main challenges 43 
of antenatal care is to identify at-risk fetuses to enable optimum surveillance and 44 
timely delivery, without intervening in pregnancies where the fetus is small but 45 
otherwise well. 46 
Fetal growth restriction (FGR, a failure of a fetus to reach its biological growth 47 
potential because of placental dysfunction) is suspected when an ultrasound 48 
estimated fetal weight (EFW) or abdominal circumference (AC) is less than the 10th 49 
percentile, or serial ultrasound examinations suggest slowing of growth velocity.3 50 
Among small for gestational age fetuses (SGA, EFW <10th centile), umbilical artery 51 
(UA) Doppler studies are routinely performed, but in the case of late-onset SGA (>32 52 
week’s gestation) UA Doppler is commonly normal.4,5 Additional Doppler studies of 53 
fetal cerebral and maternal uterine artery vascular resistance can however identify 54 
late-onset SGA pregnancies at-risk of adverse perinatal outcome.4-8 These include 55 
fetuses with an increase in fetal cerebral blood flow (including a reduction in the ratio 56 
of cerebral to umbilical artery Doppler indices i.e. a low cerebro-placental ratio, 57 
CPR), and pregnancies with high uterine artery vascular resistance. 58 
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Abnormal maternal and/or fetal Doppler studies are associated with placental 59 
pathology resulting from impaired placental angiogenesis.9,10 Placental angiogenic 60 
biomarkers present in the maternal circulation are indicators of placental function 61 
and therefore potential predictors of FGR. While alterations in early pregnancy 62 
biomarkers can predict early-onset placental-mediated disease (pre-eclampsia and 63 
FGR), prediction of late-onset FGR is poor despite 70-80% of FGR occurring late in 64 
gestation.11,12 When performed in the third trimester, the ability of biomarkers to 65 
identify placental mediated complications increases when used in high-risk 66 
populations, e.g. among suspected SGA fetuses.13-15 Among late-onset SGA 67 
pregnancies, low maternal placental growth factor (PlGF) identifies with high 68 
sensitivity FGR pregnancies with significant placental pathology.16 Low PlGF 69 
measured at the diagnosis of a small fetus may therefore be a promising antenatal 70 
discriminator between FGR and constitutionally small fetuses.  71 
In New Zealand (NZ), late-onset SGA fetuses with features of FGR (i.e. abnormal 72 
UA, CPR, UtA Doppler or EFW < 3rd customised centile) are considered high risk 73 
and guidelines recommend increased surveillance and early-term delivery.17 Fetuses 74 
without features of FGR are expectantly managed until 40 weeks’ gestation. While 75 
this ultrasound definition of FGR is consistent with international best practice,3,18 76 
serial Doppler ultrasound examinations may not be available in some NZ centres.  77 
Among late-onset SGA pregnancies, we aimed to explore the relationship between 78 
low PlGF (<5th percentile) and FGR defined by ultrasound (EFW <3rd centile and/or 79 
abnormal Doppler studies). We hypothesised that a low PlGF at diagnosis of 80 
suspected SGA would identify similar FGR pregnancies as ultrasound. Additionally, 81 
among SGA pregnancies without features of FGR on initial ultrasound, we aimed to 82 
determine whether low PlGF would identify the same FGR pregnancies as serial 83 
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Doppler measurements. Our secondary aim was to investigate the relationship 84 
between low PlGF and adverse pregnancy outcomes, including adverse perinatal 85 
outcome (operative delivery for fetal distress and/or evidence of birth asphyxia) and 86 
the development of gestational hypertensive disease. 87 
Methods 88 
Prospectively collected data were used from an historical database of suspected 89 
SGA pregnancies in Auckland, New Zealand (Ethics approval NTX/11/056/02 90 
Northern Regional Ethics Committee).19 Women were recruited between 1993 and 91 
1997 if they had a singleton pregnancy with ultrasound evidence of suspected SGA 92 
(AC <10th percentile) and no evidence of fetal abnormality. UA Doppler resistance 93 
index (RI) was performed on entry into the study. After recruitment, additional 94 
Doppler studies were performed (including UA RI, internal carotid artery (ICA) RI and 95 
UtA RI), and growth scans were performed at two weekly intervals until birth. Ten mL 96 
of maternal venous blood was taken within two weeks of recruitment. 97 
Women were excluded if they were hypertensive at the diagnosis of SGA, <32 98 
weeks’ gestational age at the time of blood sampling, had incomplete data on UA 99 
Doppler or EFW, or if there was more than two weeks between ultrasound fetal 100 
biometry and blood sampling, Figure 1. 101 
Management of the pregnancy was continued by the referring clinician, with a 102 
decision for delivery based around clinical indicators at the time. This included the 103 
recommendation that in the absence of other concerns regarding fetal wellbeing, 104 
delivery should not be undertaken on the basis of abnormal Doppler studies. 105 
Detailed demographic, antenatal, labour and birth data were collected by a research 106 
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midwife, including any fetal indication for induction of labour, operative delivery for 107 
fetal distress, or neonatal complications. 108 
Definitions 109 
Ultrasound scans and Doppler studies were performed by trained sonographers in a 110 
clinical ultrasound department using a Diasonics Masters Series (Diasonic, 111 
California, USA) or Toshiba 270 (Toshiba Medical Systems, Tokyo, Japan) 112 
ultrasound machine. Doppler studies were performed with the patient semi-113 
recumbent during fetal quiescence and apnoea. Mean RI was calculated from five 114 
waveforms. UA Doppler studies were considered abnormal if greater than the 95th 115 
percentile,20 and ICA Doppler studies were considered abnormal if the RI was less 116 
than the 10th percentile for gestational age.21 Mean RI of the right and left UtA was 117 
recorded and considered abnormal if greater than the 95th percentile for gestational 118 
age.20 CPR was defined as the ratio between the ICA and UA Dopper RI and 119 
considered abnormal if the ratio was less than the 10th percentile.22,23  120 
EFW was calculated from fetal biometry using the Hadlock 4 equation.24 EFW 121 
centiles were customised accounting for gestational age, maternal height, weight, 122 
parity and ethnicity. If maternal height or weight was unknown, NZ population 123 
median values for ethnic group were used.25 124 
At recruitment, SGA pregnancies with high-risk features on initial scan (EFW less 125 
than the 3rd customised centile, or abnormal UA Doppler study18) were classified as 126 
‘initial FGR’. SGA pregnancies with high-risk features on subsequent scanning 127 
(abnormal ICA RI, CPR, mean UtA RI or UA RI) were classified as ‘secondary FGR’. 128 
Maternal venous blood was collected by a research midwife using 10mL EDTA 129 
plasma tubes, allowed to clot at 37C for one hour and then centrifuged at 2000 rpm 130 
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for 10 minutes before storage at -80C. Samples were subsequently patch assayed 131 
for PlGF using an automated immunoassay (Triage®, Alere, San Diego, CA, USA). 132 
Low PlGF was defined as a concentration <5th percentile for gestational age.26 133 
Gestational hypertension was a diastolic blood pressure ≥90 mmHg on more than 134 
two occasions at least 6 hours apart and pre-eclampsia was gestational 135 
hypertension with proteinuria of 2+ on dipstick or >0.3g/ 24h.27 136 
Detailed labour and perinatal outcomes were collected prospectively by a research 137 
midwife. Operative delivery for fetal distress included Caesarean section (CS) or 138 
instrumental delivery with an abnormal scalp pH (<7.25) or major fetal heart rate 139 
abnormality on cardiotocograph monitoring. Adverse perinatal outcome was a 140 
composite of operative delivery for fetal distress and/or evidence of birth asphyxia 141 
(cord arterial pH <7.15 and base deficit >7 mEq/L, and/or Apgar score at 5 minutes 142 
<7).19  143 
Statistics 144 
Student’s t-test or the Mann-Whitney U–test and Chi-square or Fisher’s exact test 145 
were used as appropriate. P-values of <0.05 were considered significant. Normally 146 
distributed data were reported using means with standard deviations, while non-147 
normally distributed data using medians with interquartile ranges. Categorical data 148 
were reported using counts and proportions. 149 
Sensitivity, specificity, positive and negative predictive values of PlGF <5th centile 150 
describing FGR were calculated with 95% confidence intervals.  151 
Statistical analysis was performed using SAS© 9.4 (Cary, NY, USA).  152 
 153 
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Results 154 
We identified 259 women with SGA pregnancies and maternal serum samples. After 155 
exclusions, the initial study population included 136 women, Figure 1. Participants 156 
were enrolled at a mean gestational age of 33.3 (SD 1.7) weeks, with a median time 157 
between diagnosis of suspected SGA and PlGF test of 1.4 weeks. Women were 158 
predominantly European (59.6%), nulliparous (53.7%) and over a third were smokers 159 
(36.8%). Baseline and clinical characteristics of the study population are displayed in 160 
Table 1. Data were missing for cerebral Doppler studies (ICA / CPR) in ten 161 
pregnancies, and UtA Doppler studies in two pregnancies. 162 
Of the 136 SGA pregnancies, 56 (41.2%) had initial FGR (EFW <3rd centile n=50, 163 
abnormal UA RI n=22) while 27 (19.9%) subsequently met criteria for secondary 164 
FGR. A low PlGF was identified in 44 (32.4%) pregnancies. Overall FGR (initial or 165 
secondary) was more common among those with a low PlGF (79.6% vs. 52.2% 166 
p<0.01, Table 2). The sensitivity of PlGF <5th centile identifying FGR was 0.42 (95% 167 
CI 0.31-0.54), specificity 0.83 (0.70-0.92), positive predictive value (PPV) 0.80 (0.65-168 
0.90) and negative predictive value (NPV) 0.48 (0.37-0.59). 169 
Women with low PlGF had high rates of subsequent gestational hypertensive 170 
disease (63.6%) with all cases of pre-eclampsia occurring in this group, Table 2. At 171 
birth, two thirds of low PlGF pregnancies had a birthweight <3rd customised centile, 172 
and one third of low PlGF pregnancies experienced an adverse perinatal outcome; 173 
double the rate of the normal PlGF group, Table 2. While there were no significant 174 
differences by PLGF status in Caesarean section prior to the onset of labour, (low 175 
PlGF 13.6% vs. 5.4%, p = 0.07), rates of 5 minute Apgar score <7 (low PlGF 4.6% 176 
vs. 1.1%, p=0.21) or cord gas acidosis (low PlGF 4.6% vs. 2.2%, p=0.29), there was 177 
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a non-significant trend towards more severe outcomes among the low PlGF group. 178 
The lack of significance of these results may be due to the small numbers in the 179 
study.   180 
As initial FGR pregnancies were identified as high risk at SGA diagnosis, we 181 
investigated the role of PlGF to identify secondary FGR, i.e. FGR identified on 182 
subsequent scanning. Of 80 pregnancies, secondary FGR was diagnosed in a third 183 
(n=27, 33.8%; abnormal UtA RI n=16, UA RI n=8, ICA RI n=8, and CPR n=6) and a 184 
low PlGF was identified in 17 (21.3%). There were no significant differences in 185 
secondary FGR by PlGF status, however there was again a trend towards a higher 186 
proportion of secondary FGR among the low PlGF group (low PlGF 47.1%, normal 187 
PlGF 30.2%, p = 0.19, Table 3). The sensitivity of PlGF <5th centile identifying 188 
secondary FGR was 0.30 (95% CI 0.14-0.50), specificity 0.83 (0.70-0.92), PPV 0.47 189 
(0.23-0.72) and NPV 0.70 (0.57-0.81). 190 
Similar to the initial study population, pregnancies with low PlGF in the secondary 191 
study population were more likely to experience gestational hypertensive disease 192 
(low PlGF 58.8%, normal PlGF 12.7%, p<0.01) and were more likely to be SGA at 193 
birth (low PlGF 88.2%, normal PlGF 54.0%, p=0.01), Table 3. There were no 194 
differences in adverse perinatal outcome, but numbers were low. 195 
Sensitivity analyses were performed, excluding those with missing ICA and/or UtA 196 
Dopplers (n=11). No differences in statistical significance were seen, and negligible 197 
differences in test performance characteristics were observed. 198 
 199 
Discussion 200 
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In this historical cohort of late-onset SGA pregnancies, low PlGF identified 201 
pregnancies that were at risk of both severe growth restriction and adverse perinatal 202 
outcome, predominantly due to operative delivery for fetal distress. Low PlGF 203 
therefore identified a more severe FGR phenotype associated with poor placental 204 
function and subsequent intolerance of labour, consistent with the association 205 
previously seen between low PlGF and placental FGR.16 Low PlGF was also strongly 206 
associated with the later development of gestational hypertensive diseases. 207 
However low PlGF did not reliably identify the same high-risk pregnancies as 208 
detailed Doppler ultrasound investigations. Low PlGF is therefore not an adequate 209 
replacement for serial detailed ultrasound Doppler measurements to identify high risk 210 
SGA pregnancies. 211 
Only one study in a European cohort has investigated whether angiogenic placental 212 
biomarkers (including PlGF) in late-onset SGA can identify pregnancies at-risk of 213 
adverse outcome.28 Among SGA pregnancies diagnosed on routine third-trimester 214 
ultrasound, they found that angiogenic biomarkers had a similar predictive value to 215 
serial Doppler indices in identifying high risk late-onset SGA pregnancies. Their 216 
analyses included SGA pregnancies with high-risk ultrasound features at initial 217 
evaluation (EFW <3rd centile or abnormal UA RI). We excluded these pregnancies in 218 
our analyses as these pregnancies are identified as high risk requiring additional 219 
surveillance regardless of PlGF result. In the remaining SGA pregnancies where 220 
FGR status is initially unknown, serial fetal Doppler interrogation is recommended 221 
and a single blood test to identify high-risk pregnancies would potentially be time- 222 
and cost-effective. However, our findings do not support the use of PlGF in this 223 
setting.  224 
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Low PlGF in late pregnancy has been shown to identify SGA pregnancies with 225 
significant placental pathology.16,29 An abnormal UA RI is likewise associated with 226 
extensive vascular placental changes,30 however a significant proportion of SGA 227 
pregnancies with normal umbilical artery Doppler studies also have histological 228 
evidence of poor placental perfusion.31 We found that while pregnancies with an 229 
abnormal UA RI were more likely to have a low PlGF, 20% of pregnancies with an 230 
abnormal UA RI had a normal PlGF. This indicates a complex relationship between 231 
low PlGF, abnormal Doppler studies and placental pathology. 232 
Our findings in a cohort of late-onset SGA pregnancies support the association 233 
between low PlGF and adverse pregnancy outcomes, including hypertensive 234 
disease.28 In our cohort, over two thirds of pregnancies with low PlGF went on to 235 
develop gestational hypertension or pre-eclampsia, suggesting PlGF may be 236 
clinically useful among SGA pregnancies to identify those at greatest risk of 237 
subsequent hypertensive complications.  238 
Ultrasound is a limited resource in NZ, particularly in regional areas where the skills 239 
required to perform uterine and fetal cerebral Doppler studies may not be available. 240 
Transfer to a secondary hospital for these examinations can be costly and time-241 
consuming. Without access to serial detailed Doppler examination, elective delivery 242 
is recommended by 38-39 weeks’ gestation,17 which may be an unnecessary 243 
intervention in otherwise low risk SGA pregnancies. Unfortunately our data suggest 244 
that PlGF is not a substitute for more detailed Doppler investigations in SGA 245 
pregnancies. 246 
Strengths 247 
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This cohort study had prospective collection of data including serial Doppler 248 
measurements linked with labour and birth outcome data and a biobank.  249 
Limitations 250 
As our data are historical, it is limited to what was collected and part of clinical 251 
practice at that time. Doppler studies at that time utilised RI instead of pulsatility 252 
index (PI), which is now considered best practice. Additionally, fetal cerebral blood 253 
flow was assessed using ICA Doppler, while currently middle cerebral artery (MCA) 254 
Doppler studies are standard. However, blood flow through the ICA is a surrogate for 255 
MCA blood flow and a CPR of <1 is independent of Doppler measurement type (RI 256 
vs PI) and is associated with increased perinatal risk.23 In our population a CPR <1 257 
identified the same pregnancies as a CPR <10th centile.  258 
The management of SGA pregnancies at the time of data collection was not 259 
standardised. In particular an abnormal Doppler study didn’t necessarily necessitate 260 
elective delivery, although increased surveillance was common. As a result, analysis 261 
of outcomes by FGR status would be misleading as it does not reflect current 262 
obstetric practice. We were therefore unable to include a comparison of outcomes 263 
between FGR and low PlGF pregnancies. 264 
Overall this study had low numbers, particularly among our secondary study 265 
population. A larger sample size would have allowed for more robust evaluation of 266 
outcomes, however it is unlikely to have raised the test performance of PlGF to a 267 
point where it would be able to replace serial Doppler examinations.  268 
Conclusion 269 
We report that while low PlGF at the time of late-onset SGA diagnosis is associated 270 
with increased perinatal risk, it does not adequately identify at-risk FGR infants 271 
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classified using detailed Doppler studies. The measurement of PlGF in these women 272 
therefore cannot be considered an adequate replacement for serial Doppler 273 
investigations. Low PlGF is strongly associated with subsequent development of 274 
gestational hypertensive disease and therefore may be of clinical utility. Due to the 275 
historical nature of these data, our findings should be confirmed by repeating this 276 
analysis in a contemporary cohort. 277 
  278 
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Figure 1: Flowchart of study population of women with suspected small for 383 
gestational age (SGA) pregnancies, defined as an abdominal circumference <10th 384 
centile. FGR, fetal growth restriction (abnormal umbilical artery Doppler resistance 385 
index and/or estimated fetal weight <3rd centile); PlGF, placental growth factor. 386 
*more than one exclusion may apply so numbers do not total. 387 
 388 
  389 
20 
 
 
 
Table 1: Clinical characteristics of the full cohort study population (n=136) 390 
Characteristic Value* 
Demographics  
Age (y) 26.4 (5.3) 
Weight† (kg) 63.1 (13.6) 
Body Mass Index‡ 22.5 (20.4-25.4) 
Ethnicity  
European 81 (59.6%) 
Maori 23 (16.9%) 
Pacific 13 (9.6%) 
Asian 16 (11.8%) 
Other 3 (2.2%) 
Nulliparous 73 (53.7%) 
Smoker 50 (36.8%) 
At enrolment  
Gestational age at enrolment (weeks) 33.3 (1.7) 
Gestational age at PlGF measurement (weeks) 35.0 (1.5) 
EFW customised centile 5.05 (1.5-10.8) 
Maternal outcomes  
Gestational hypertension 34 (25.0%) 
Pre-eclampsia 8 (5.9%) 
Delivery outcomes  
Gestational age at delivery (weeks) 38.0 (1.7) 
Preterm delivery (<37 weeks) 33 (24.3%) 
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IOL for fetal indication 96 (70.6%) 
CS or instrumental delivery for fetal distress 25 (18.4%) 
CS  before labour for fetal distress 11 (8.1%) 
Emergency CS in labour for fetal distress 7 (5.2%) 
Instrumental delivery for fetal distress 7 (5.2%) 
Birthweight (g) 2530 (479) 
Birthweight customised centile 5.1 (2.0-11.9) 
<10th customised centile 103 (75.7%) 
<3rd customised centile 60 (44.1%) 
Neonatal  
Apgar score <7 at 5 min 3 (2.2%) 
Cord arterial blood gas acidosis  4 (2.9%) 
NICU admission >48 h 33 (24.3%) 
Adverse perinatal outcome§ 29 (21.3%) 
* mean (SD), median (IQR) or n (%) as appropriate 391 
† n=27 missing 392 
‡ n=44 missing 393 
§ Adverse perinatal outcome: operative delivery for fetal distress and/or evidence of 394 
birth asphyxia (cord arterial pH <7.15 and base deficit >7 mEq/L, and/or Apgar score 395 
at 5 minutes <7). 396 
 397 
EFW, estimated fetal weight; IOL, induction of labour; CS, Caesarean section; NICU, 398 
neonatal intensive care unit 399 
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Table 2: Low PlGF and pregnancy outcome within the full cohort study population 400 
(n=136) 401 
 PlGF <5th 
centile 
N=44 (32.4%) 
PlGF>5th 
centile 
N=92 (67.6%) 
P-
value 
Antenatal    
Gestational age at PlGF (weeks) 34.6 (1.4) 35.2 (1.5) 0.02 
EFW (g) 1871 (321) 2130 (365) <0.01 
EFW customised centile 2.8 (0.6-6.4) 6.2 (2.4-11.8) 0.02 
EFW <3rd customised centile 24 (54.6%) 26 (28.3%) <0.01 
Abnormal Doppler study (RI)    
Umbilical artery (>95th percentile)20 18 (40.9%) 18 (19.6%) <0.01 
ICA (<10th percentile)*21 9 (20.5%) 8 (8.7%) 0.04 
CPR (<10th percentile)*21, 23 13 (30.0%) 11 (12.0%) <0.01 
Mean uterine (>95th percentile)20† 15 (34.1%) 16 (17.4%) 0.04 
Fetal growth restriction‡ 35 (79.6%) 48 (52.2%) <0.01 
Maternal     
Gestational hypertension 20 (45.5%) 14 (15.2%) <0.01 
Pre-eclampsia 8 (18.2%) 0 <0.01 
Delivery     
Gestational age at delivery (w) 36.8 (1.6) 38.6 (1.5) <0.01 
Preterm delivery (<37w) 20 (45.5%) 13 (14.1%) <0.01 
Birthweight (g) 2183 (408) 2697 (419) <0.01 
Birthweight customised centile 2.2 (0.3-6.7) 6.8 (2.8-18.0) <0.01 
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<10th customised centile 42 (95.5%) 61 (66.3%) <0.01 
<3rd customised centile 29 (65.9%) 31 (33.7%) <0.01 
IOL for fetal indication 31 (70.5%) 65 (70.7%) 0.98 
CS or instrumental delivery for fetal 
distress 
13 (29.6%) 12 (13.0%) 0.02 
Adverse perinatal outcome§ 15 (34.1%) 14 (15.2%) 0.01 
* missing n=10 (PlGF <5th centile n=5, PlGF >5th centile n=5) 402 
† missing n=2 (PlGF <5th centile n=0, PlGF >5th centile n=2) 403 
‡ Estimated fetal weight <3rd customised centile or abnormal Doppler (umbilical 404 
artery RI, internal carotid RI, cerebro-perfusion ratio or mean uterine artery RI) 405 
§ Operative delivery for fetal distress and/or evidence of birth asphyxia (cord arterial 406 
pH <7.15 and base deficit >7 mEq/L, and/or Apgar score at 5 minutes <7) 407 
 408 
PlGF, placental growth factor; EFW, estimated fetal weight; RI, resistance index; 409 
ICA, internal carotid artery; CPR, cerebral perfusion ratio; IOL, induction of labour; 410 
CS, Caesarean section.  411 
 412 
  413 
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Table 3: Low PlGF and pregnancy outcome in small for gestational age pregnancies 414 
without initial features of fetal growth restriction (n=80) 415 
 PlGF <5th 
centile 
N=17 (21.3%) 
PlGF>5th 
centile 
N=63 (78.7%) 
P-
value 
Antenatal    
Gestational age at PlGF (weeks) 34.9 (1.2) 35.2 (1.5) 0.50 
EFW (g) 2098 (263) 2230 (356) 0.16 
EFW customised centile 9.8 (6.2-13.3) 8.2 (5.5-14.3) 0.34 
Abnormal Doppler study (RI)    
Umbilical artery (>95th percentile)20 1 (5.9%) 7 (11.1%) 0.32 
ICA (<10th percentile)*21 3 (21.4%) 5 (8.1%) 0.12 
CPR (<10th percentile)*21, 23 2 (14.3%) 4 (6.4%) 0.23 
Mean uterine artery (>95th percentile)20 4 (23.5%) 12 (19.1%) 0.24 
Secondary fetal growth restriction† 8 (47.1%) 19 (30.2%) 0.19 
Maternal     
Gestational hypertension 9 (52.9%) 8 (12.7%) <0.01 
Pre-eclampsia 1 (5.9%) 0 <0.21 
Delivery     
Gestational age at delivery (weeks) 37.5 (1.3) 38.8 (1.3) <0.01 
Preterm delivery (<37 weeks) 5 (29.4%) 6 (9.5%) 0.04 
Birthweight (g) 2467 (305) 2830 (382) <0.01 
Birthweight customised centile 7.6 (4.2-11.3) 9.5 (5.4-20.9) 0.05 
<10th customised centile 15 (88.2%) 34 (54.0%) 0.01 
25 
 
 
 
<3rd customised centile 6 (35.3 %) 13 (20.6%) 0.11 
IOL for fetal indication 12 (70.6%) 39 (61.9%) 0.51 
CS or instrumental delivery for fetal 
distress 
2 (11.8%) 8 (12.7%) 0.32 
Adverse perinatal outcome‡ 3 (17.7%) 10 (15.9%) 0.28 
* missing n=4 (PlGF <5th centile n=3, PlGF>5th centile n=1) 416 
† Abnormal Doppler RI (umbilical artery, internal carotid, cerebro-perfusion ratio or 417 
mean uterine artery) 418 
‡ Operative delivery for fetal distress and/or evidence of birth asphyxia (cord arterial 419 
pH <7.15 and base deficit >7 mEq/L, and/or Apgar score at 5 minutes <7). 420 
 421 
PlGF, placental growth factor; FGR, fetal growth restriction; EFW, estimated fetal 422 
weight; RI, resistance index; ICA, internal carotid artery; CPR, cerebral placental 423 
ratio; IOL, induction of labour; CS, Caesarean section. 424 
 425 
 426 
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